Baker Avenue Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Baker Avenue Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$595K	Sell	3,530 -160	-4%	-$23.7K	0.01%	438
2026 Q1	$486K	Buy	+3,690	New	+$490K	0.01%	433
2023 Q4	–	Sell	-68	Closed	-$7.65K	–	1081
2023 Q3	$7.65K	Buy	68 +55	+423%	+$5.79K	﹤0.01%	828
2023 Q2	$1.23K	Sell	13 -3	-19%	-$293	﹤0.01%	1115
2023 Q1	$1.62K	Sell	16 -15	-48%	-$1.56K	﹤0.01%	1039
2022 Q4	$3.7K	Buy	+31	New	+$3.63K	﹤0.01%	853
2014 Q3	–	Sell	-17,980	Closed	-$267K	–	296
2014 Q2	$267K	Buy	+17,980	New	+$254K	0.04%	238
2014 Q1	–	Sell	-16,500	Closed	-$154K	–	244
2013 Q4	$154K	Buy	16,500 +3,500	+27%	+$34.2K	0.03%	244
2013 Q3	$147K	Buy	+13,000	New	+$179K	0.03%	213

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Baker Avenue Asset Management's NBIX Position: Q2 2026 in Review

Baker Avenue Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 4.3% in Q2 2026, selling an estimated $23.7K and leaving 3,530 shares worth $595K. The position accounts for 0.01% of the portfolio, ranked #438.

Baker Avenue Asset Management first reported a position in NBIX in Q3 2013 and has held it in 9 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Baker Avenue Asset Management held 3,530 shares of Neurocrine Biosciences worth $595K as of Q2 2026.
Baker Avenue Asset Management sold 160 Neurocrine Biosciences shares in Q2 2026, an estimated $23.7K.
Neurocrine Biosciences made up 0.01% of Baker Avenue Asset Management's portfolio in Q2 2026, its #438 holding.
Baker Avenue Asset Management first reported a position in Neurocrine Biosciences in Q3 2013 and has held it in 9 quarters since.
772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Baker Avenue Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.